

**Sample Name** LORAZEPAM INJECTION-IP. **Mfg Lic No** [REDACTED]  
**Submitted By** Quality Control Advisor. (MMDSL) Shillong. **Report No** [REDACTED]  
**Address** DHS LaitumkhrahNHM, EastKhasi Hills Meghalaya. **Receipt Date** 19-Sep-24  
**Mfg By** N.S. **Report Date** 07-Oct-24  
**Supplied By** N.S. **Ref No** - N.S.  
**Batch No** MMDSL/QC-0495 **Mfg. Date** 07/2024 **Exp Date** 06/2026 **Batch Size** N.S. **Sample Qty** 30 AMPOULES

### TEST RESULTS

Date / Period of Performance of test 19/09/2024 to 07/10/2024.

Reference to protocol :- I.P-2022.

Description :- Clear colourless solution filled in amber colour glass ampoules.

Identification (by HPLC) :- Complies.

Lorazepam related compound B:- Not detected. Limit:NMT 0.1%  
(by HPLC)

Related Substances (by HPLC) :- Complies.

Extractable volume :- 2.04ml.

Particulate matter :- Complies.

Sterility :- Complies with the test for sterility.

Bacterial endotoxins :- Less than 100.0EU/mg of Lorazepam Limit NMT 100.0EU/mg of Lorazepam.

Assay (by HPLC) :- Each ml. contains:-

Contents of	Obtained	Claim	Lower	LIMIT		Method
				Upper		
Lorazepam	:- 1.98mg	2.0mg.	1.8mg.	2.2mg.		IP.

NOTE:- SAMPLE CONSUMED IN TESTING.

Report: In Opinion of the undersigned, The sample referred as defined in the Act and the rules made there under per IP.

